Salute e Benessere

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac…

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next milestone in the execution of its oncology strategyCureVac shareholders receive approximately $5.46 in BioNTech American Depositary Shares for each CureVac share, subject to a collar; an indicative exchange ratio will be available at www.envisionreports.com/CureVacOfferfor the duration of the exchange offer...
Nasdaq GlobeNewswire
22/10/2025

JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic…

Approval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the absolute change from baseline in Forced Vital Capacity at 52 weeks with nerandomilast 18 mg and 9 mg versus placebo in adults with idiopathic pulmonary fibrosis (IPF) 1,2 Nerandomilast was included in the priority review by the Centre for Drug Evaluation (CDE) of the NMPA in January this year, and was recently granted FDA approval in the United States....
Nasdaq GlobeNewswire
22/10/2025

Cambrex Unveils $120 Million Investment to Expand API Manufacturing and…

The $120 million investment will support a 40% increase in the Charles City, Iowa site's large-scale manufacturing capacity, reaching nearly one million liters. The Charles City facility, situated on a 45-acre site, manufactures a broad range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. The$120 millioninvestment will support a 40% increase in theCharles City, Iowasite's large-scale manufacturing capacity, reaching nearly one million…
PR Newswire
22/10/2025

Oticon announces world's first hearing aids with Google's Fast Pair: Oticon…

"We are immensely proud to bring Google's Fast Pair to our LE Audio hearing aids. Oticon Intent and Oticon Zeal are the world's first hearing aids to offer Google Fast Pair, a testament to our strong collaboration with Google. Together, we have pioneered the most effortless way to connect Oticon LE Audio hearing aids to Android LE Audio devices, setting a new standard for accessibility, to the benefit of millions of hearing aid users across the globe," says Frederik Gundelach, Senior…
PR Newswire
22/10/2025

Europe Leads Dental Implants Market Growth to 2030 with Zirconia Implants…

Geographic Segment Insights Geographic Segment Insights Europecontinues to dominate the dental implant landscape, supported by strong clinical expertise, high patient spending power, and an established training ecosystem. Growing emphasis on long-term implant maintenance has encouraged manufacturers to integrate follow-up solutions into their product offerings, strengthening brand loyalty among dental professionals. InAsia-Pacific, the market is expanding rapidly as rising dental...
PR Newswire
22/10/2025

/C O R R E C T I O N -- Taiwan Institute of Economic Research/

FRANKFURT, Germany, Oct. 22, 2025 /PRNewswire/ -- Taiwan's healthcare system, ranked No. 1 worldwide in CEOWORLD Magazine's 2024 Health Care Index, is built on the integration of modern medicine with proven Traditional Chinese Medicine (TCM). At CPHI Frankfurt 2025, organized by Taiwan Institute of Economic Research, the Taiwan Traditional Chinese Medicine Pavilion (stand 12.1 C112) will highlight how Taiwan combines scientific validation with centuries of herbal wisdom to create innovative…
PR Newswire
22/10/2025

Industry-Leading Vinyl Range Sets New Standard in Glue-Down Flooring

Why this range stands out: Why this range stands out: "This collection reflects what our customers are looking for, flooring that performs exceptionally well, looks fantastic, and keeps things simple," Richard, Director of Flooring365.co.uk shared. "We're proud to offer one of the most comprehensive glue-down vinyl ranges on the market." The launch marks a major step forward in Flooring365.co.uk's mission to deliver exceptional flooring at accessible prices. With an unmatched…
PR Newswire
22/10/2025

Alvotech Announces Changes in Global Business Development and Commercial…

REYKJAVIK, ICELAND (OCTOBER 21, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its global business development and commercial operations team. Anil Okay, Chief Commercial Officer, is stepping down to serve as Chief Executive Officer of Adalvo. Trisha Durant has joined Alvotech as Senior Vice President, Global Business Development and Commercial Operation,...
Nasdaq GlobeNewswire
22/10/2025

EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction…

EQT Life Sciences invested in the business in 2017, as part of a syndicate of investors, and has since provided comprehensive support, including at the board level. EQT Life Sciences invested in the business in 2017, as part of a syndicate of investors, and has since provided comprehensive support, including at the board level. Vincent Brichard, Venture Partner at EQT Life Sciences and board member at ImCheck Therapeutics, said : "We are immensely proud to have supported ImCheck's…
PR Newswire
22/10/2025

BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES

On September 15, 2025, the Company issued Debentures for an aggregate principal amount of $335,670 convertible into common shares in the capital of the Company ("Shares") at any time, at the option of the holders thereof, at the closing price of the Shares on the Canadian Securities Exchange (the "CSE") on the day notice of conversion is received by the Company, subject to the pricing requirements in the policies of the CSE. The Debentures bear interest at a rate of 10% per…
PR Newswire
22/10/2025

Onco3R Therapeutics reports first pre-clinical data from its best-in-class…

Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivatorCandidates for FGFR3 and SMARCA2 programs identified: IND enabling studies anticipated in mid-2026 Leuven, Belgium, October 22, 2025. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced that it will present...
Nasdaq GlobeNewswire
22/10/2025

Berlin Heals Welcomes Dr. Eric Fain as New Board Member

Dr. Eric Fain commented: "Developing technology to treat heart failure is a true passion of mine and so I am honored to join Berlin Heals at such a pivotal moment in the company's development and strategic planning. C-MIC technology has the potential to be a true breakthrough in the treatment of these difficult to manage patients and to greatly improve patient outcomes and quality of life across the broad spectrum of chronic heart failure." Dr.Eric Faincommented: "Developing…
PR Newswire
22/10/2025

Nomination Committee appointed for SciBase Holding's Annual General Meeting in…

Derek Maetzold (Castle Biosciences Inc) Derek Maetzold(Castle Biosciences Inc) Maria Anderkvist (Coeli Wealth Management), Jesper Høiland (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding onJune 17, 2025.The Annual General Meeting of SciBase Holding AB (publ) will be held onMay 19, 2026...
PR Newswire
22/10/2025

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from…

Early clinical data indicate that these preclinical findings are translating into humans. In patients with advanced solid tumors, intramuscular administration of ACM-CpG - at weekly or biweekly doses as low as 0.25mg CpG – has demonstrated robust systemic immune activation as evidenced through immune biomarker data. The therapy shows a highly favorable safety and tolerability profile and to date, no dose-limiting toxicities have been observed. Early clinical data indicate that these…
PR Newswire
22/10/2025

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial…

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 52 1 Trial showed reduction in annual cumulative steroid dose vs placebo through Week 52; safety profile consistent with known profile of Cosentyx 1 Data highlight potential of Cosentyx as novel targeted PMR treatment, second most common inflammatory disease in adults ≥50 2, with limited options available Basel, October 22, 2025 – Novartis today...
Nasdaq GlobeNewswire
22/10/2025

Ipsen delivers strong sales in the first nine months of 2025 and further…

Year-to-date total sales growth of 12.1% at CER 1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosion of Somatuline® and accelerated sales growth of the rest of the portfolio: total sales growth of around 10.0% 2at CER (prior guidance greater than 7.0%); core operating margin of around 35.0% of total sales (prior...
Nasdaq GlobeNewswire
22/10/2025

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline…

Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48.00 per Share, in cash, without interest and subject to any applicable...
Nasdaq GlobeNewswire
22/10/2025

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology…

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire all issued and outstanding shares of ImCheck Therapeutics, for which ImCheck Therapeutics’ shareholders will be eligible to receive a closing...
Nasdaq GlobeNewswire
22/10/2025

Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary…

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 studyEfdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a...
Nasdaq GlobeNewswire
22/10/2025

Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends…

Emphysema Market Summary Emphysema Market Summary Discover the emphysema new treatment @New Treatments for Emphysema Key Factors Driving the Growth of the Emphysema Market Rising Prevalence of Emphysema and COPD The increasing prevalence of COPD, including emphysema, is a primary driver. Factors such as smoking, air pollution, and genetic predispositions contribute to this rise. In 2024, DelveInsight estimated that the 7MM had around31 milliondiagnosed cases of...
PR Newswire
21/10/2025

Momcozy partners with The Modern Midwife to tackle mums' biggest feeding…

The Q&A is part of a wider Momcozy Brand Day initiative working with the UK's largest online parenting community, Mumsnet. With millions of mums visiting every month, Marie will be answering real mum concerns and challenges with tangible advice and product recommendations that can make the experience easier and more comfortable for both parent and baby. The Q&A is part of a wider Momcozy Brand Day initiative working with the UK's largest online parenting community, Mumsnet. With millions…
PR Newswire
21/10/2025

Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has acquired an additional $200,000 worth of Ethereum (ETH), bringing the Company’s total investment in ETH to $2 million.This purchase was executed under Cosmos Health’s previously announced $300 million digital assets facility, which underpins the Company’s strategy to broaden and strengthen its portfolio through targeted...
Nasdaq GlobeNewswire
21/10/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 42 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from October 13th to October 17th 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1113/10/2025FR001025915069...
Nasdaq GlobeNewswire
21/10/2025

Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year

Curia’s Burlington site has been part of the company’s network since 2010. The facility specializes in drug product manufacturing of vials and prefilled syringes for late-stage clinical trials and commercial products. The site is known for its capabilities to handle solvent-based processes, highly viscous products and controlled substances. It also houses an on-site process development lab supporting mixing studies, scale-up and formulation development.“Curia employees play a crucial role...
Nasdaq GlobeNewswire
21/10/2025
Altri  Comunicati